BioCryst Pharma
BCRX----
BioCryst Pharma (BCRX)
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The c...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
BioCryst Pharma Analyst Rating
View MoreForecast & Rating
Jul 20, 2026Price forecast
$21.00124.84%
Forecast & RatingStrong buy
11analysts
- Strong buy63.64%
- Buy27.27%
- Hold9.09%
- Sell0.00%
- Strong sell0.00%
News
- Simplywall · 2 days ago, 04:14 AM
How Investors May Respond To BioCryst (BCRX) Hiring Its First CSO To Drive Rare-Disease Deals
- Unusual Whales · Jul 22 at 06:58 AM
BioCryst to Report Second Quarter 2026 Financial Results on August 5
- PUBT · Jul 22 at 06:04 AM
BioCryst to report Q2 2026 results, host conference call and webcast
- Simplywall · Jul 20 at 08:19 AM
Can BioCryst Pharmaceuticals (BCRX) Be Worth More As A New CSO Sharpens Its Pipeline Story?
- rttnews · Jul 15 at 06:35 AM
BioCryst Pharmaceuticals Appoints David Jenkins As Chief Scientific Officer
- Simplywall · Jul 12 at 08:07 AM
BioCryst Pharmaceuticals (BCRX) Reshapes R And D As Fair Value Narrative Stays In Focus
